The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma.
about
Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapyFrom structure to redox: The diverse functional roles of disulfides and implications in disease.Quantitative Proteomics and Lipidomics Analysis of Endoplasmic Reticulum of Macrophage Infected with Mycobacterium tuberculosisProtein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6.Protein Co-Expression Analysis as a Strategy to Complement a Standard Quantitative Proteomics Approach: Case of a Glioblastoma Multiforme Study.Activation of surrogate death receptor signaling triggers peroxynitrite-dependent execution of cisplatin-resistant cancer cells.Exposure to atheroma-relevant 7-oxysterols causes proteomic alterations in cell death, cellular longevity, and lipid metabolism in THP-1 macrophagesMicrosomal membrane proteome of low grade diffuse astrocytomas: Differentially expressed proteins and candidate surveillance biomarkers.Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/β-catenin signaling pathway.Human protein secretory pathway genes are expressed in a tissue-specific pattern to match processing demands of the secretome.Differential protein expression profile in the hypothalamic GT1-7 cell line after exposure to anabolic androgenic steroids.Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.Cancer and necroptosis: friend or foe?Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.Emerging roles of protein disulfide isomerase in cancer.Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer.Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.
P2860
Q26739959-823D85A0-360E-455F-ADDF-760B671DFFFEQ30397007-7CB4576A-FD7B-413B-8FCE-B0F29ABFB6E4Q35133816-A6DB22DF-72FC-4BB2-8D45-EAA83E5EB37AQ36021520-B620FD78-0200-4360-9E65-FFF940761FAFQ36115923-1F65A16D-8041-4782-AC7F-1FE447797572Q36246491-DBD86AA8-AF48-47E0-A59F-70E65554B9A2Q36325670-FA9BCDA7-5223-420D-841F-8F65FD5F1C63Q36953938-1D7486E4-A75F-42AF-B6C3-B1E9591B9715Q37374550-BBC4FE04-0729-4040-9A66-8B2E3B1478B1Q37619742-4F3AB4ED-A09B-4893-BFEF-E1408F6D3CF0Q38606264-FFDA199E-F90F-4001-B050-F072F955A591Q38696931-428DD361-B2E6-4F2E-926C-67389EBF396DQ38748131-DEC4EA86-0988-408D-97B4-1641AC814911Q38799139-15648223-E237-42DC-A4CD-3401CFD7F240Q38868212-32CA47C3-BBC2-4F99-A09B-F674F17FB644Q42357758-6F5B87EA-4F57-41E6-84B8-CB878192E772Q47098483-9952041A-CA7A-4EF8-8DCC-A3585748A1EFQ48236551-1ED4A324-C222-44E0-838E-D5F27AB08EDAQ50986588-444B0EAA-078A-4666-8EE9-BD00485E9CC8
P2860
The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@en
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@nl
type
label
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@en
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@nl
prefLabel
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@en
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@nl
P2093
P2860
P356
P1476
The protein disulfide isomeras ...... death in lung adenocarcinoma.
@en
P2093
A W E Jones
C Boursier
C Gallerne
D D Esposti
G Szabadkai
P2860
P2888
P304
P356
10.1038/CDD.2013.193
P577
2014-01-24T00:00:00Z